Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (101-110 of 164) with videos related to

Pageof 17
Sort By:
Blood|August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.
The Lancet. Oncology|October 29, 2011
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialAnas Younes, Yasuhiro Oki, R Gregory Bociek, et al.
British Journal of Haematology|April 7, 2017
Characteristics, management, and outcomes of patients with follicular dendritic cell sarcomaPreetesh Jain, Sarah A Milgrom, Keyur P Patel, et al.
The Oncologist|August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation BurdenWinnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Leukemia & Lymphoma|March 16, 2013
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphomaBouthaina S Dabaja, Jack Phan, Osama Mawlawi, et al.
Leukemia & Lymphoma|March 26, 2015
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trialMeghan Karuturi, Anas Younes, Luis Fayad, et al.
Leukemia & Lymphoma|August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphomaBei Hu, Anas Younes, Jason R Westin, et al.
Leukemia & Lymphoma|November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R<sup>2</sup> ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Pageof 17

Showing results (101-110 of 164) with videos related to

Sort By:
Pageof 17
Blood|August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.
The Lancet. Oncology|October 29, 2011
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialAnas Younes, Yasuhiro Oki, R Gregory Bociek, et al.
British Journal of Haematology|April 7, 2017
Characteristics, management, and outcomes of patients with follicular dendritic cell sarcomaPreetesh Jain, Sarah A Milgrom, Keyur P Patel, et al.
The Oncologist|August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation BurdenWinnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Leukemia & Lymphoma|March 16, 2013
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphomaBouthaina S Dabaja, Jack Phan, Osama Mawlawi, et al.
Leukemia & Lymphoma|March 26, 2015
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trialMeghan Karuturi, Anas Younes, Luis Fayad, et al.
Leukemia & Lymphoma|August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphomaBei Hu, Anas Younes, Jason R Westin, et al.
Leukemia & Lymphoma|November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R<sup>2</sup> ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Pageof 17